<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179828</url>
  </required_header>
  <id_info>
    <org_study_id>KEK 213/09</org_study_id>
    <secondary_id>grant: SPUM no. 33CM30_124117</secondary_id>
    <nct_id>NCT01179828</nct_id>
  </id_info>
  <brief_title>Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)</brief_title>
  <acronym>Predictio</acronym>
  <official_title>Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug therapy in patients with chronic low back pain is a major challenge for physicians. One
      of the problems is the lacking knowledge in prediction of drug efficacy in a chosen patient.
      Usually one of the classes of pain medication is given to patients with a similar clinical
      picture, although different pain mechanisms may be responsible for this clinical picture.

      Another reason for variable drug efficacy are genetic polymorphisms, this may be the reason
      why an unique drug produces different responses (from a lacking analgesic effect up to
      excessive effect or side-effects.

      Quantitative sensory testing is a method that documents alterations in the pain perception
      system. Linking genetic polymorphisms to quantitative sensory testing may give us a tool for
      anticipation of drug efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Drug therapy is an essential part of pain treatment. However, only a minor part of pain
      patients benefits from the available treatments or is able to tolerate the drugs. One
      important limitation of drug therapy is lack of instruments to predict their effect. Indeed,
      in clinical practice &quot;classes&quot; of drugs (e.g. antidepressants) are given to &quot;classes&quot; of
      patients (e.g. neuropathic pain patients). However, within those classes of patients very
      different pain mechanisms are likely to underlie the pain condition in different patients. If
      drugs affect part of these mechanisms, they will not work in all patients. Another reason for
      variability in drug responses is genetic variation leading to a spectrum of different
      responses to analgesics, from lack of efficacy to exaggerated responses, up to intolerable
      adverse effects.

      Quantitative sensory testing comprises methods that document alterations and reorganization
      of the nociceptive system. Measuring an abnormal result in a chronic pain patient may provide
      us with the information that the underlying pain pathways somehow must be altered. An
      essential question is whether this information can be linked to drug efficacy in a
      mechanism-based treatment approach. A further important question is whether assessing genetic
      polymorphisms can explain different drug effects and hence help selecting the appropriate
      therapeutic strategy for individual patients.

      Objective

      We will test the hypothesis that there is a correlation between disturbances in specific pain
      mechanisms as assessed by quantitative sensory tests and analgesic efficacy after single-dose
      drug administration in patients with chronic low back pain. Genetic factors affecting drug
      metabolism and pain sensitivity will be analyzed as additional explanatory variables for drug
      efficacy.

      Methods

      Quantitative sensory testing: Heat pain threshold and tolerance, Ice water testing with
      central modulation of nociceptive input (DNIC), electrical pain detection and temporal
      summation (skin probe), pressure algometry with pain detection and threshold Drugs
      investigated: Imipramine, Oxycodone, Clobazam Blood samples: pharmacogenetics: Cytochrome
      variants CYP2D6, CYP2C19, CYP3A4, COMT haplotypes, CGH-1 variants, A118G of mu opioid
      receptor gene variants pharmacokinetics: kinetics of imipramine and desipramine
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in NRS(pain scale) between measurement after and before drug administration</measure>
    <time_frame>07/2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients global impression of change scale after drug administration</measure>
    <time_frame>07/2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic variables(see before)</measure>
    <time_frame>07/2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: measure of Imipramine and desipramine blood levels</measure>
    <time_frame>07/2012</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reliability of repeated quantitative sensory testing in the same patient</measure>
    <time_frame>12/2010</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxycodone 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobazam 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imipramine 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tolterodine 1mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 15mg</intervention_name>
    <description>15mg single administration p.o.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobazam</intervention_name>
    <description>20mg single administration p.o.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>75mg single administration p.o.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolterodine</intervention_name>
    <description>1 mg single administration p.o.</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low back pain with NRS&gt;2

          -  Chronic low back pain since more than 6 months

        Exclusion Criteria

          -  pregnancy

          -  use of pain medication other than paracetamol and ibuprofen in the last 7 days

          -  suspicion of radicular pain

          -  suspicion of intervertebral disk herniation

          -  foraminal intervertebral stenosis

          -  suspicion of polyneuropathy

          -  diabetes

          -  parkinson disease

          -  alzheimer disease

          -  glaucoma

          -  prostata hyperplasia or voiding problems

          -  known heart rhythm problems

          -  heart insufficiency NYHA 3-4

          -  Systemic inflammatory disease

          -  Ongoing oncologic disease

          -  drug or alcohol abuse

          -  Significant depressive disease (BDI-FS&gt;9)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Curatolo, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Siegenthaler, Dr Med</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal H Vuilleumier, Dr Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bern, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Andreas Siegenthaler</name>
      <address>
        <city>Dep. of Anesthesiolgy and Pain therapy</city>
        <state>Bern University Hospital</state>
        <zip>3010 Bern</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005454. Review.</citation>
    <PMID>17943857</PMID>
  </reference>
  <results_reference>
    <citation>Arendt-Nielsen L, Yarnitsky D. Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera. J Pain. 2009 Jun;10(6):556-72. doi: 10.1016/j.jpain.2009.02.002. Epub 2009 Apr 19. Review.</citation>
    <PMID>19380256</PMID>
  </results_reference>
  <results_reference>
    <citation>Foulkes T, Wood JN. Pain genes. PLoS Genet. 2008 Jul 25;4(7):e1000086. doi: 10.1371/journal.pgen.1000086. Review.</citation>
    <PMID>18654615</PMID>
  </results_reference>
  <results_reference>
    <citation>Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: mechanisms and clinical implications. Phys Med Rehabil Clin N Am. 2006 May;17(2):287-302. Review.</citation>
    <PMID>16616268</PMID>
  </results_reference>
  <results_reference>
    <citation>Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005 Nov-Dec;21(6):524-35.</citation>
    <PMID>16215338</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <name_title>Dr Med Andreas Siegenthaler</name_title>
    <organization>Inselspital Bern</organization>
  </responsible_party>
  <keyword>Quantitative sensory testing</keyword>
  <keyword>Drug efficacy</keyword>
  <keyword>Low back pain syndrome</keyword>
  <keyword>Imipramine</keyword>
  <keyword>Oxycodone</keyword>
  <keyword>Clobazam</keyword>
  <keyword>Tolterodine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Imipramine</mesh_term>
    <mesh_term>Clobazam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

